XLRN News and Press, Acceleron Pharma Inc. From 12/01/20

The FDA has designated Orphan Drug status to Acceleron Pharma's (XLRN) ACE-1334 for the treatment of systemic sclerosis, an autoimmune rheumatic disease characterized by excessive production and accumulation of collagen, called fibrosis, in the skin and internal organs.The Company intend...

– Company plans to initiate Phase 1b/Phase 2 trial in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) in 2021 – – ACE-1334 previously received Fast Track designation from the FDA – Acceleron Pharma Inc. (Nas...

Biotech stocks should be on investors’ radars due to the COVID-19 pandemic. A few of them have also made significant progress in developing a vaccine or a treatment for the deadly infection. Besides, biotech companies are also playing a crucial role in developing treatments for other d...

Acceleron Pharma ([[XLRN]] -1.8%) announces new data from two Phase 2 clinical trials, SPECTRA and PULSAR, evaluating sotatercept in patients with pulmonary arterial hypertension ((PAH)).Preliminary results from 10 participants in SPECTRA showed that treated patients experienced substantial i...

– Treatment with sotatercept in first set of patients in the ongoing SPECTRA Phase 2 trial was associated with substantial improvements in hemodynamics, exercise tolerance and exercise capacity at week 24 – – Sotatercept was generally well tolerated, consi...

– Treatment with sotatercept in the ongoing PULSAR Phase 2 trial was associated with improvements in cardiac and pulmonary function at week 24 – – Presentation of echocardiography data from the PULSAR trial received AHA’s “Cardiopulmonary Bes...

Geron's only therapeutic candidate currently undergoing a Phase III trial has superior efficacy. The consensus has underestimated its sales potential, and the shares have yet to reach the 2018 high. Subject to regulatory approvals, a swift achievement of the fullest sales potentia...

– Presentation of cardiac and pulmonary function data from the ongoing PULSAR Phase 2 trial receives AHA’s “Cardiopulmonary Best Abstract” Award – – AHA sessions to include data from the ongoing SPECTRA Phase 2 trial – &...

Acceleron Pharma Inc. (XLRN) Q3 2020 Earnings Conference Call November 05, 2020 05:00 PM ET Company Participants Jamie Bernard - Associate Director of Investor Relations Habib Dable - Chief Executive Officer Kevin McLaughlin - Chief Financial Officer Jay Backstrom - Head of Research & Dev...

The following slide deck was published by Acceleron Pharma Inc. in conjunction with their 2020 Q3 earnings call. For further details see: Acceleron Pharma Inc. 2020 Q3 - Results - Earnings Call Presentation